New Scientific Publication

Apmonia Therapeutics’ lead program (AP-01 or TAX2) is a cyclic peptide targeting TSP-1 (a ligand of CD47 receptor) across various tumor indications with high unmet medical needs.

Beyond our oncology expertise, our innovative technological approach interfering with TSP-1/CD47 signaling may improve the lives of a large fraction of the (aging) population, such as people suffering from cardiovascular diseases.

Check out out pioneering results newly published in ATVB An American Heart Association Journal establishing Apmonia Tx’ asset as a new strategy of high therapeutic interest in controlling platelet activation and related thrombotic disorders, while being associated with a favorable safety profile and low bleeding risk.


More :

Share this post

Share on facebook
Share on linkedin
Share on twitter
Share on email

More to explore

Overall News

Welcome to Reims 2019

Apmonia Therapeutics is honored and delighted to have been elected as most promising #startup of the year during “Welcome to Reims” event last week. We